Hydroxychloroquine availability during COVID-19 crisis and its effect on patient anxiety
Objective To report the results of a survey exploring the experience of patients with SLE facing hydroxychloroquine (HCQ) shortage that occurred during the early phases of the COVID-19 pandemic.Methods A survey was designed by Lupus Europe’s patient advisory network and distributed through its socia...
Saved in:
| Main Authors: | Alain Cornet, Chiara Tani, Marta Mosca, Jeanette Andersen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-04-01
|
| Series: | Lupus Science and Medicine |
| Online Access: | https://lupus.bmj.com/content/8/1/e000496.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence
by: Ronald F van Vollenhoven, et al.
Published: (2021-04-01) -
Analysis of hydroxychloroquine prescriptions for COVID‐19 in Japan
by: Takashi Watari, et al.
Published: (2023-05-01) -
Hydroxychloroquine in COVID-19 widespread use despite unproven benefit
by: Pranav Ish
Published: (2022-01-01) -
Hydroxychloroquine Effects on TLR Signalling: Underexposed but Unneglectable in COVID-19
by: Aliede E. in ‘t Veld, et al.
Published: (2021-01-01) -
COVID-19 Pneumonia in Patients on Chronic Hydroxychloroquine Therapy: Three Cases of COVID-19 Pneumonia
by: Awan K. Rahman, et al.
Published: (2020-01-01)